Laekna Limited
Clinical trials sponsored by Laekna Limited, explained in plain language.
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise against resistant ovarian cancer
Disease control CompletedThis Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
New drug LAE102 put to the test in healthy women
Knowledge-focused CompletedThis early-stage study tested a new drug called LAE102 in 32 healthy postmenopausal women to see if it is safe and how the body processes it. Participants received either a single dose of LAE102 or a placebo. The main goal was to check for side effects, not to treat any disease.
Phase: PHASE1 • Sponsor: Laekna Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC